Amalgamated Financial’s Eterna Therapeutics ERNA Stock Holding History

Amalgamated Financial’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$10K	Buy	+1	New	+$19K	﹤0.01%	2895

Other funds holding ERNA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's ERNA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Eterna Therapeutics (ERNA) in Q1 2022: 1 share worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #2895 among its holdings.

49 funds tracked by Wall St. Rank hold ERNA as of Q1 2022.

Amalgamated Financial held 1 share of Eterna Therapeutics worth $10K as of Q1 2022.
Eterna Therapeutics was a new Amalgamated Financial position in Q1 2022.
Eterna Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2895 holding.
49 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.